Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Evaluates Potential Link Between Bisphosphonate Class And Atrial Fibrillation

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent journal articles on the osteoporosis products’ association with atrial fibrillation spark an “early safety communication" from the agency.

You may also be interested in...



FDA Warns About Musculoskeletal Pain With Bisphosphonate Use

Agency asks physicians to consider discontinuing treatment despite lack of causal link to pain.

FDA Warns About Musculoskeletal Pain With Bisphosphonate Use

Agency asks physicians to consider discontinuing treatment despite lack of causal link to pain.

Teva Gains ANDA Approval For Generic Actonel

Firm awaits Delaware federal court decision on pending litigation with Actonel marketer Procter & Gamble.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel